After decades of stalled progress, a new wave of clinical research involving psychedelic compounds shows promising results for treating depression, addiction, PTSD, and other mental health conditions.
Mindspace is committed to exploring the potential of this exciting new field and preparing for the eventual advent of wider-access psychedelic-assisted psychotherapy, including:
- supporting research efforts into the therapeutic potential of ketamine, psilocybin, MDMA and 5meoDMT
- offering integration support for psychedelic experiences as part of our psychology clinic offering
- contributing to continuing education efforts to help train new therapists in this unique modality
- facilitating dialogue between the clinical mindfulness and psychedelic communities
In November 2019 Mindspace offered Psychedelics 101 & 102 for Clinicians for this first time in Canada—a 2-day training facilitated by psychologists Ingmar Gorman and Elizabeth Nielson designed for clinicians and healthcare providers who want to learn more about current psychedelic research and clinical practice, including how to work with patients who have a history of psychedelic use or have expressed an interest in using psychedelics.
Sign up to stay abreast of events and announcements related to psychedelics at Mindspace